{"transactions":[{"id":680020,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T20:10:05.000Z","date":"2026-08-18","kind":"sale","planned":true,"acquired":false,"shares":551,"price":10.3,"value":5675.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.16 to $10.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":12114,"source":{"system":"sec-edgar","filing":"0001866219-26-000010","document":"form4-08202026_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000186621926000010/form4-08202026_040801.xml","form_type":"4"}},{"id":729564,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-23T23:49:25.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":14180,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date."}],"balance_after":14180,"derivative":{"underlying":"Common Stock","underlying_shares":14180},"source":{"system":"sec-edgar","filing":"0001104659-26-076922","document":"tm2618639-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465926076922/tm2618639-1_4seq1.xml","form_type":"4"}},{"id":729563,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-23T23:49:25.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":21270,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date."}],"balance_after":21270,"derivative":{"exercise_price":9.13,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":21270},"source":{"system":"sec-edgar","filing":"0001104659-26-076922","document":"tm2618639-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465926076922/tm2618639-1_4seq1.xml","form_type":"4"}},{"id":737964,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-15T20:15:25.000Z","date":"2026-06-11","kind":"sale","planned":true,"acquired":false,"shares":550,"price":10.04,"value":5522.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.83 to $10.16 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":12665,"source":{"system":"sec-edgar","filing":"0001866219-26-000007","document":"form4-06152026_080616.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000186621926000007/form4-06152026_080616.xml","form_type":"4"}},{"id":744804,"issuer":{"id":6276,"kind":"organization","name":"Coherus Oncology, Inc."},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-09T22:39:55.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":1.45,"expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001610717-26-000200","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000161071726000200/form4.xml","form_type":"4"}},{"id":744803,"issuer":{"id":6276,"kind":"organization","name":"Coherus Oncology, Inc."},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-06-09T22:39:55.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting.  100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001610717-26-000200","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000161071726000200/form4.xml","form_type":"4"}},{"id":799254,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-04-28T21:00:12.000Z","date":"2026-04-25","kind":"exercise","planned":false,"acquired":false,"shares":9520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Company common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs subject to this grant under the Plan will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of April 25, 2025, in each case subject to continued service on the Company's Board of Directors through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs subject to this grant under the Plan will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of April 25, 2025, in each case subject to continued service on the Company's Board of Directors through such vesting date."}],"balance_after":19040,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":9520},"source":{"system":"sec-edgar","filing":"0001104659-26-050457","document":"tm2612977-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465926050457/tm2612977-1_4seq1.xml","form_type":"4"}},{"id":799253,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-28T21:00:12.000Z","date":"2026-04-25","kind":"exercise","planned":false,"acquired":true,"shares":9520,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":9520,"source":{"system":"sec-edgar","filing":"0001104659-26-050457","document":"tm2612977-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465926050457/tm2612977-1_4seq1.xml","form_type":"4"}},{"id":848907,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-11T20:39:18.000Z","date":"2026-03-09","kind":"grant","planned":false,"acquired":true,"shares":14788,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option shall vest over a three-year period in equal quarterly installments with the first such vesting to occur on June 9, 2026, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":14788,"derivative":{"exercise_price":11.35,"expiration_date":"2036-03-08","underlying":"Common Stock","underlying_shares":14788},"source":{"system":"sec-edgar","filing":"0001866219-26-000005","document":"form4-03112026_080314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000186621926000005/form4-03112026_080314.xml","form_type":"4"}},{"id":848906,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-11T20:39:18.000Z","date":"2026-03-09","kind":"grant","planned":false,"acquired":true,"shares":13215,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs shall vest over a three-year period in twelve equal quarterly installments with the first such vesting to occur on May 15, 2026, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":13215,"source":{"system":"sec-edgar","filing":"0001866219-26-000005","document":"form4-03112026_080314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000186621926000005/form4-03112026_080314.xml","form_type":"4"}},{"id":1058352,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-22T20:03:25.000Z","date":"2025-08-21","kind":"sale","planned":false,"acquired":false,"shares":1453,"price":10.544,"value":15320.432,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.49 to $10.64 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":15306,"source":{"system":"sec-edgar","filing":"0001415889-25-022741","document":"form4-08222025_080821.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000141588925022741/form4-08222025_080821.xml","form_type":"4"}},{"id":1058351,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-22T20:03:25.000Z","date":"2025-08-20","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to performance-based restricted stock units granted to the reporting person on February 9, 2024, 4,000 shares were issued on the Transaction Date upon the achievement of certain performance criteria certified by the compensation committee of the Issuer's board of directors on the Transaction Date and 4,000 shares will be issued on August 20, 2026, subject to the reporting person providing service through such date."}],"balance_after":16759,"source":{"system":"sec-edgar","filing":"0001415889-25-022741","document":"form4-08222025_080821.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000141588925022741/form4-08222025_080821.xml","form_type":"4"}},{"id":1067911,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-14T01:06:02.000Z","date":"2025-08-12","kind":"sale","planned":false,"acquired":false,"shares":136,"price":10.338,"value":1405.968,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.120 to $10.415 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split."}],"balance_after":8759,"source":{"system":"sec-edgar","filing":"0001415889-25-021691","document":"form4-08142025_010858.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000141588925021691/form4-08142025_010858.xml","form_type":"4"}},{"id":1067910,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-14T01:06:02.000Z","date":"2025-08-11","kind":"sale","planned":false,"acquired":false,"shares":131,"price":10.526,"value":1378.906,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.045 to $11.00 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Fonn 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 390 shares acquired on May 18, 2025 under the Issuer's 2021 Employee Stock Purchase Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split."}],"balance_after":8895,"source":{"system":"sec-edgar","filing":"0001415889-25-021691","document":"form4-08142025_010858.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000141588925021691/form4-08142025_010858.xml","form_type":"4"}},{"id":1111969,"issuer":{"id":6276,"kind":"organization","name":"Coherus Oncology, Inc."},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-13T22:47:41.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":112000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the one year anniversary of June 11, 2025, subject to Reporting Person's continued service relationship with the Issuer on such vesting date."}],"balance_after":112000,"derivative":{"exercise_price":0.7904,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":112000},"source":{"system":"sec-edgar","filing":"0001610717-25-000223","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000161071725000223/form4.xml","form_type":"4"}},{"id":1147626,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2025-05-15T20:33:54.000Z","date":"2025-05-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12050,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":3.93,"underlying":"Common Stock","underlying_shares":12050},"source":{"system":"sec-edgar","filing":"0001562180-25-003881","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000156218025003881/primarydocument.xml","form_type":"4"}},{"id":1147625,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2025-05-15T20:33:54.000Z","date":"2025-05-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":33400,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":4.54,"underlying":"Common Stock","underlying_shares":33400},"source":{"system":"sec-edgar","filing":"0001562180-25-003881","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000156218025003881/primarydocument.xml","form_type":"4"}},{"id":1147624,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-15T20:33:54.000Z","date":"2025-05-13","kind":"other","planned":false,"acquired":false,"shares":5533,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the \"Company Common Stock\"), for a price per share of $5.00 (the \"Merger Consideration\"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-25-003881","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000156218025003881/primarydocument.xml","form_type":"4"}},{"id":1147623,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-15T20:33:54.000Z","date":"2025-05-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17092,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the \"Company Common Stock\"), for a price per share of $5.00 (the \"Merger Consideration\"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a \"Company RSU Award\"), whether vested or unvested that was outstanding immediately prior to the effective time of the Merger (the \"Effective Time\"), became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration."}],"balance_after":5533,"source":{"system":"sec-edgar","filing":"0001562180-25-003881","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000156218025003881/primarydocument.xml","form_type":"4"}},{"id":1164333,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-04-29T12:08:08.000Z","date":"2025-04-25","kind":"grant","planned":false,"acquired":true,"shares":28560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Company common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs subject to this grant under the Plan will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued service on the Company's Board of Directors through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs subject to this grant under the Plan will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued service on the Company's Board of Directors through such vesting date."}],"balance_after":28560,"derivative":{"underlying":"Common Stock","underlying_shares":28560},"source":{"system":"sec-edgar","filing":"0001104659-25-040669","document":"tm2513375-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925040669/tm2513375-2_4seq1.xml","form_type":"4"}},{"id":1164332,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2025-04-29T12:08:08.000Z","date":"2025-04-25","kind":"grant","planned":false,"acquired":true,"shares":42840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option grant under the Novavax, Inc. (the \"Company\") Amended and Restated 2015 Stock Incentive Plan, as amended (the \"Plan\"), will vest with respect to one-third (1/3) of the shares on each of the first three (3) anniversaries of the April 25, 2025 grant date (the \"Grant Date\"), in each case subject to continued service on the Company's Board of Directors through such vesting date."}],"balance_after":42840,"derivative":{"exercise_price":6.7,"exercise_date":"2026-04-25","expiration_date":"2035-04-25","underlying":"Common Stock","underlying_shares":42840},"source":{"system":"sec-edgar","filing":"0001104659-25-040669","document":"tm2513375-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925040669/tm2513375-2_4seq1.xml","form_type":"4"}},{"id":1200339,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-18T23:01:35.000Z","date":"2025-03-17","kind":"purchase","planned":false,"acquired":true,"shares":200000,"price":0.5581,"value":111620.0,"ownership":{"direct":false,"nature":"Co-grantor and Co-trustee"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported above reflects the weighted average price of the shares purchased. These shares were purchased in multiple transactions at prices ranging from $0.54 to $0.56, inclusive. Upon request from the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this range"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by The Charles & Lisa Newton Living Trust.  The Reporting Person is co-trustee and co-grantor of The Charles & Lisa Newton Living Trust."}],"balance_after":200000,"source":{"system":"sec-edgar","filing":"0001415889-25-008517","document":"form4-03182025_110331.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000141588925008517/form4-03182025_110331.xml","form_type":"4"}},{"id":1243493,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2025-02-27T00:29:34.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":56250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The reported transaction involved the reporting person's receipt of a grant of performance-based options, subject to vesting upon the achievement of specified performance criteria."}],"balance_after":56250,"derivative":{"exercise_price":0.5535,"expiration_date":"2035-02-09","underlying":"Common Stock","underlying_shares":56250},"source":{"system":"sec-edgar","filing":"0001415889-25-005753","document":"form4-02272025_120230.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000141588925005753/form4-02272025_120230.xml","form_type":"4"}},{"id":1243492,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2025-02-27T00:29:34.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"12.5% of the option shares will vest on August 9, 2025, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date."}],"balance_after":450000,"derivative":{"exercise_price":0.5535,"expiration_date":"2035-02-09","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001415889-25-005753","document":"form4-02272025_120230.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000141588925005753/form4-02272025_120230.xml","form_type":"4"}},{"id":1243491,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-27T00:29:34.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"12.5% of the total number of restricted stock units will vest on August 9, 2025, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting\ndate"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 7,800 shares acquired on May 17, 2024 and 3,696 shares acquired on November 18, 2024 under the Issuer's 2021 Employee Stock Purchase Plan."}],"balance_after":172725,"source":{"system":"sec-edgar","filing":"0001415889-25-005753","document":"form4-02272025_120230.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000141588925005753/form4-02272025_120230.xml","form_type":"4"}},{"id":1482261,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2024-06-12T22:52:24.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":12050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests 100% on the earlier of June 10, 2025 or the date of the next annual meeting of stockholders of 2seventy bio, Inc."}],"balance_after":12050,"derivative":{"exercise_price":3.93,"expiration_date":"2034-06-10","underlying":"Common Stock","underlying_shares":12050},"source":{"system":"sec-edgar","filing":"0001562180-24-005007","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000156218024005007/primarydocument.xml","form_type":"4"}},{"id":1482260,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-12T22:52:24.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":6025,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These restricted stock units vest 100% on the earlier of June 10, 2025 or the date of the next annual meeting of stockholders of 2seventy bio, Inc."}],"balance_after":22625,"source":{"system":"sec-edgar","filing":"0001562180-24-005007","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000156218024005007/primarydocument.xml","form_type":"4"}},{"id":1490295,"issuer":{"id":6276,"kind":"organization","name":"Coherus Oncology, Inc."},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-05T22:52:49.000Z","date":"2024-06-03","kind":"grant","planned":false,"acquired":true,"shares":112000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the one year anniversary of June 3, 2024, subject to Reporting Person's continued service relationship with the Issuer on such vesting date."}],"balance_after":112000,"derivative":{"exercise_price":1.76,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":112000},"source":{"system":"sec-edgar","filing":"0001610717-24-000292","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000161071724000292/form4.xml","form_type":"4"}},{"id":1562032,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2024-03-25T20:28:11.000Z","date":"2024-03-20","kind":"grant","planned":false,"acquired":true,"shares":33400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option vests ratably over three years in annual installments with the first installment vesting on March 20, 2025, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":33400,"derivative":{"exercise_price":4.54,"expiration_date":"2034-03-20","underlying":"Common Stock","underlying_shares":33400},"source":{"system":"sec-edgar","filing":"0001562180-24-002976","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000156218024002976/primarydocument.xml","form_type":"4"}},{"id":1562031,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-25T20:28:11.000Z","date":"2024-03-20","kind":"grant","planned":false,"acquired":true,"shares":16600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This restricted stock unit award vests ratably over three years in annual installments with the first installment vesting on March 20, 2025, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":16600,"source":{"system":"sec-edgar","filing":"0001562180-24-002976","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000156218024002976/primarydocument.xml","form_type":"4"}},{"id":1646537,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-14T01:19:16.000Z","date":"2024-02-09","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"12.5% of the option shares shall vest on August 9, 2024, with the remaining option shares to vest in equal monthly installments over the following forty-two months."}],"balance_after":400000,"derivative":{"exercise_price":1.8,"expiration_date":"2034-02-08","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001209191-24-003270","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000120919124003270/doc4.xml","form_type":"4"}},{"id":1646536,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-02-14T01:19:16.000Z","date":"2024-02-09","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of performance-based restricted stock units, subject to vesting upon the achievement of specified performance criteria. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,941 shares acquired on May 18, 2022, 5,787 shares acquired on May 18, 2023 and 1 share acquired on November 17, 2023 under the Issuer's 2021 Employee Stock Purchase Plan."}],"balance_after":48729,"source":{"system":"sec-edgar","filing":"0001209191-24-003270","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000120919124003270/doc4.xml","form_type":"4"}},{"id":1734862,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-21T01:55:59.000Z","date":"2023-11-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on November 16, 2023 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"12.5% of the option shares vested on August 9, 2022, with the remaining option shares to vest in equal monthly installments over the following forty-two months."}],"balance_after":0,"derivative":{"exercise_price":5.98,"expiration_date":"2032-03-15","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001209191-23-056181","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000120919123056181/doc4.xml","form_type":"4"}},{"id":1734861,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-21T01:55:59.000Z","date":"2023-11-16","kind":"grant","planned":false,"acquired":true,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on November 16, 2023 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"218,750 shares were vested as of November 16, 2023 and the remaining unvested shares will vest in equal monthly installments over the following thirty-nine months based on the original vesting commencement date."}],"balance_after":500000,"derivative":{"exercise_price":1.87,"expiration_date":"2032-03-15","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001209191-23-056181","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000120919123056181/doc4.xml","form_type":"4"}},{"id":1734860,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-21T01:55:59.000Z","date":"2023-11-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":516000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on November 16, 2023 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"1/48th of the total shares vest in equal monthly installments over the forty-eight months following June 16, 2021."}],"balance_after":0,"derivative":{"exercise_price":6.24,"expiration_date":"2031-02-04","underlying":"Common Stock","underlying_shares":516000},"source":{"system":"sec-edgar","filing":"0001209191-23-056181","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000120919123056181/doc4.xml","form_type":"4"}},{"id":1734859,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-21T01:55:59.000Z","date":"2023-11-16","kind":"grant","planned":false,"acquired":true,"shares":516000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on November 16, 2023 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"311,750 shares were vested as of November 16, 2023 and the remaining unvested shares will vest in equal monthly installments over the following thirty-one months based on the original vesting commencement date."}],"balance_after":516000,"derivative":{"exercise_price":1.87,"expiration_date":"2031-02-04","underlying":"Common Stock","underlying_shares":516000},"source":{"system":"sec-edgar","filing":"0001209191-23-056181","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000120919123056181/doc4.xml","form_type":"4"}},{"id":1734858,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-21T01:55:59.000Z","date":"2023-11-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":190000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on November 16, 2023 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/4 of the option shares vested on February 5, 2022, with the remaining option shares vesting in equal monthly installments over the following thirty-six months."}],"balance_after":0,"derivative":{"exercise_price":6.24,"expiration_date":"2031-02-04","underlying":"Common Stock","underlying_shares":190000},"source":{"system":"sec-edgar","filing":"0001209191-23-056181","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000120919123056181/doc4.xml","form_type":"4"}},{"id":1734857,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-21T01:55:59.000Z","date":"2023-11-16","kind":"grant","planned":false,"acquired":true,"shares":190000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on November 16, 2023 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"130,625 shares were vested as of November 16, 2023 and the remaining unvested shares will vest in equal monthly installments over the following twenty-seven months based on the original vesting commencement date."}],"balance_after":190000,"derivative":{"exercise_price":1.87,"expiration_date":"2031-02-04","underlying":"Common Stock","underlying_shares":190000},"source":{"system":"sec-edgar","filing":"0001209191-23-056181","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000120919123056181/doc4.xml","form_type":"4"}},{"id":1734856,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-21T01:55:59.000Z","date":"2023-11-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3612000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on November 16, 2023 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/4 of the option shares vested on February 5, 2022, with the remaining option shares vesting in equal monthly installments over the following thirty-six months."}],"balance_after":0,"derivative":{"exercise_price":6.24,"expiration_date":"2031-02-04","underlying":"Common Stock","underlying_shares":3612000},"source":{"system":"sec-edgar","filing":"0001209191-23-056181","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000120919123056181/doc4.xml","form_type":"4"}},{"id":1734855,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-21T01:55:59.000Z","date":"2023-11-16","kind":"grant","planned":false,"acquired":true,"shares":3612000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on November 16, 2023 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"2,483,250 shares were vested as of November 16, 2023 and the remaining unvested shares will vest in equal monthly installments over the following twenty-seven months based on the original vesting commencement date."}],"balance_after":3612000,"derivative":{"exercise_price":1.87,"expiration_date":"2031-02-04","underlying":"Common Stock","underlying_shares":3612000},"source":{"system":"sec-edgar","filing":"0001209191-23-056181","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000120919123056181/doc4.xml","form_type":"4"}},{"id":1860875,"issuer":{"id":6276,"kind":"organization","name":"Coherus Oncology, Inc."},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-09T20:56:22.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":38250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from June 7, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":38250,"derivative":{"exercise_price":5.38,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":38250},"source":{"system":"sec-edgar","filing":"0001610717-23-000117","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000161071723000117/form4.xml","form_type":"4"}},{"id":1987467,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2023-02-28T23:13:13.000Z","date":"2023-02-24","kind":"grant","acquired":true,"shares":700000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"12.5% of the option shares shall vest on August 9, 2023, with the remaining option shares to vest in equal monthly installments over the following forty-two months."}],"balance_after":700000,"derivative":{"exercise_price":2.13,"expiration_date":"2033-02-23","underlying":"Common Stock","underlying_shares":700000},"source":{"system":"sec-edgar","filing":"0001209191-23-013836","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000120919123013836/doc4.xml","form_type":"4"}},{"id":2279486,"issuer":{"id":6276,"kind":"organization","name":"Coherus Oncology, Inc."},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-06T22:50:55.000Z","date":"2022-05-04","kind":"grant","acquired":true,"shares":54000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 1/36th of the total number of shares subject to the option in successive, equal monthly installments measured from May 4, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":54000,"derivative":{"exercise_price":9.72,"expiration_date":"2032-05-04","underlying":"Common Stock","underlying_shares":54000},"source":{"system":"sec-edgar","filing":"0001567619-22-009712","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000156761922009712/doc1.xml","form_type":"4"}},{"id":2324979,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2022-03-18T20:09:10.000Z","date":"2022-03-16","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"12.5% of the option shares shall vest on August 9, 2022, with the remaining option shares to vest in equal monthly installments over the following forty-two months."}],"balance_after":500000,"derivative":{"exercise_price":5.98,"expiration_date":"2032-03-15","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001209191-22-020006","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000120919122020006/doc4.xml","form_type":"4"}}]}